Sofosbuvir/Velpatasvir Prophylaxis for 12 Weeks in Hepatitis C Virus (HCV)-Negative Recipients Receiving Kidney Transplantation from HCV-Positive Donors

07 September 2021: Original Paper

Ruoyang Chen ^BCEF* , Dawei Li ^BCDFG* , Ming Zhang ^AC , Xiaodong Yuan ^ADEF*

DOI: 10.12659/AOT.933313

Ann Transplant 2021; 26:e933313

Table 2 Viremic parameter of donor and recipient before and after transplantation.

Recipient				Donor		Paired recipient

HCV RNA IU/mL			HCV Ab	Genotype	HCV RNA IU/mL
^*	^#	^*	^*	3a	583	1

0	0	0	0.37/0.11	1b	369000	2

0	0	0	0.04/0.2	2a	727000	3

0	0	0	0.06/0.04	1b	168000	4

0	0	0	2.07/1.68	3b	147000	5

0	0	0	1.72/1.29	3a	654000	6

0	0	0	0.11

0	0	0	0.02	2a	342000	7

0	0	0	0.08/0.09	3b	113000	8

0	0	0	0.05	1b	217000	9

0	0	0	0.04/0.07	3a	668000	10

0	0	0	0.42	2a	438000	11

0	0	0	0.09/0.08	3a	935000	12

0	0	0	0.03/0.07	3b	477000	13

0	0	0	0.2/0.08	1b	537000	14

0	0	0	0.08/0.05	3b	1100000	15
^* ot – on treatment of antiviral therapy; ^# fu – follow-up after antiviral treatment.